PROCORE TECHNOLOGIES, INC.

**Signal Note: Eventide PCOR Initiation** Eventide's $1.1M PCOR entry is notable given the firm's strict values-based screening and biotech focus—this signals conviction in construction software's ESG profile and recurring revenue model rather than traditional drug development. The position likely reflects Eventide's thesis on operational efficiency in regulated industries, though the initiation size is modest relative to typical biotech holdings, suggesting either a portfolio-building entry or measured conviction at current valuations.